Related Experiment Video
Updated: Apr 21, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Drug-eluting stents in unprotected left main coronary artery disease
1Interventional Cardiology Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza OMS 1, Bergamo, Italy.
Insights
Drug-eluting stents (DES) offer a viable alternative to coronary artery bypass graft surgery for unprotected left main coronary artery disease. While DES show comparable hard endpoints and fewer complications, increased revascularization rates warrant careful patient selection.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Surgery
Background:
- Unprotected left main coronary artery (ULMCA) disease traditionally treated with coronary artery bypass graft surgery (CABG).
- Emerging evidence supports percutaneous coronary intervention (PCI) as an alternative in select patients.
- Drug-eluting stents (DES) have demonstrated comparable efficacy to CABG for hard endpoints in ULMCA disease.
Purpose of the Study:
- To review the role and outcomes of DES in managing ULMCA disease.
- To compare DES versus CABG for ULMCA disease.
- To highlight factors influencing outcomes in ULMCA stenting.
Main Methods:
- Review of current literature on DES and CABG for ULMCA disease.
- Analysis of clinical trial data comparing DES and CABG.
- Discussion of patient selection criteria and procedural considerations.
Main Results:
- DES show similar rates of hard endpoints compared to CABG.
- DES are associated with fewer periprocedural complications and lower stroke rates.
- Increased rates of revascularization are noted with DES over time.
- Outcomes are influenced by patient clinical characteristics, anatomical complexity, and operator experience.
Conclusions:
- DES represent a feasible alternative to CABG for ULMCA disease, particularly in patients with lower anatomical complexity.
- Careful patient selection, advanced DES technology, and procedural expertise are crucial for optimal outcomes.
- Ongoing research is essential to further refine treatment strategies for ULMCA disease.
Abstract:
Though coronary bypass graft surgery (CABG) has traditionally been the cornerstone of therapy in patients with unprotected left main coronary artery (ULMCA) disease, recent evidence supports the use of percutaneous coronary intervention in appropriate patients. Indeed in patients with ULMCA disease, drug-eluting stents (DES) have shown similar incidence of hard end points, fewer periprocedural complications and lower stroke rates compared with CABG, though at the cost of increased revascularization with time. Furthermore, the availability of newer efficacious and safer DES as well as improvements in diagnostic tools, percutaneous techniques and, importantly, a better patient selection, allowed percutaneous coronary intervention a viable alternative to CABG of left main-patients with low disease complexity; however, even in this interventional era characterized by efficacious DES, patients with ULMCA disease remain a challenging high-risk population where outcomes strongly depend on clinical characteristics, anatomical disease complexity and extension and operator's experience. This review summarizes the role of DES in ULMCA disease patients.
Related Concept Videos
01:24Cardiac Catheterization III: Left Heart Catheterization
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care